Lars Christophersen
Overview
Explore the profile of Lars Christophersen including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
28
Citations
553
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
11.
Shaqour B, Aizawa J, Guarch-Perez C, Gorecka Z, Christophersen L, Martinet W, et al.
Pharmaceutics
. 2021 Jun;
13(6).
PMID: 34064276
Additive manufacturing is widely used to produce highly complex structures. Moreover, this technology has proven its superiority in producing tools which can be used in different applications. We designed and...
12.
Laulund A, Schwartz F, Trostrup H, Thomsen K, Christophersen L, Calum H, et al.
Front Cell Infect Microbiol
. 2021 Apr;
11:652012.
PMID: 33912476
Objective: is known to contribute to the pathogenesis of chronic wounds by biofilm-establishment with increased tolerance to host response and antibiotics. The neutrophil-factor S100A8/A9 has a promising adjuvant effect when...
13.
Thomsen K, Christophersen L, Lerche C, Holmgaard D, Calum H, Hoiby N, et al.
Int J Antimicrob Agents
. 2020 Dec;
57(1):106213.
PMID: 33256950
Cystic fibrosis (CF) patients are at risk of acquiring chronic Pseudomonas aeruginosa lung infections. The biofilm mode of growth of P. aeruginosa induces tolerance to antibiotics and the host response;...
14.
Christophersen L, Schwartz F, Lerche C, Svanekjaer T, Kragh K, Laulund A, et al.
J Cyst Fibros
. 2020 Feb;
19(6):996-1003.
PMID: 32067957
Background: Pseudomonas aeruginosa is difficult to eradicate from the lungs of cystic fibrosis (CF) patients due to biofilm formation. Organs and blood are independent pharmacokinetic (PK) compartments. Previously, we showed...
15.
Laulund A, Trostrup H, Lerche C, Thomsen K, Christophersen L, Calum H, et al.
Pathog Dis
. 2019 May;
78(5).
PMID: 31116394
Materials/methods: Thirty-two mice were injected with alginate-embedded P. aeruginosa following a third-degree burn. The mice were randomized into four groups receiving combination ciprofloxacin and S100A8/A9 or monotherapy ciprofloxacin, S100A8/A9 or...
16.
Granslo H, Fredheim E, Esaiassen E, Christophersen L, Jensen P, Mollnes T, et al.
APMIS
. 2019 Mar;
127(6):475-483.
PMID: 30916807
The global spread of antimicrobial resistance and the increasing number of immune-compromised patients are major challenges in modern medicine. Targeting bacterial virulence or the human host immune system to increase...
17.
Trostrup H, Lerche C, Christophersen L, Jensen P, Hoiby N, Moser C
Int J Mol Sci
. 2017 Jul;
18(7).
PMID: 28672877
biofilm maintains and perturbs local host defense, hindering timely wound healing. Previously, we showed that suppressed S100A8/A9 of the murine innate host defense. We assessed the potential antimicrobial effect of...
18.
Cao B, Christophersen L, Kolpen M, Jensen P, Sneppen K, Hoiby N, et al.
PLoS One
. 2016 Apr;
11(4):e0153616.
PMID: 27100887
Microbial cells embedded in a self-produced extracellular biofilm matrix cause chronic infections, e. g. by Pseudomonas aeruginosa in the lungs of cystic fibrosis patients. The antibiotic killing of bacteria in...
19.
Trostrup H, Holstein P, Christophersen L, Jorgensen B, Karlsmark T, Hoiby N, et al.
Arch Dermatol Res
. 2016 Apr;
308(5):347-55.
PMID: 27084691
Chronic wounds and in particular diabetic foot ulcers (DFUs) are a growing clinical challenge, but the underlying molecular pathophysiological mechanisms are unclear. Recently, we reported reduced levels of the immunomodulating...
20.
Damlund D, Christophersen L, Jensen P, Alhede M, Hoiby N, Moser C
APMIS
. 2016 Mar;
124(6):500-7.
PMID: 27009697
The majority of cystic fibrosis (CF) patients acquire chronic Pseudomonas aeruginosa lung infection, resulting in increased mortality and morbidity. The chronic P. aeruginosa lung infection is characterized by bacteria growing...